Company data sheet · Novo Nordisk
Novo Nordisk: growth far beyond its economy.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- Denmark
- Ticker
- NVO (NYSE)
- Sources
- SEC filings (2001–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Denmark
- Data as of
- October 18, 2026
- It outgrew its own economy many times over. Revenue rose from DKK 122 billion in 2019 to DKK 309 billion in 2025: 2.5 times as much. Denmark's economy, counted the same way in money terms, grew about 35%. Whatever drove it, the economy around it does not account for growth of that size.
- Two decisions on record. Stratrix has verified two of Novo Nordisk's big decisions, each with what happened next.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2019 | DKK 122 billion | DKK 39 billion | |
| 2020 | DKK 127 billion | DKK 42.1 billion | |
| 2021 | DKK 141 billion | DKK 47.8 billion | |
| 2022 | DKK 177 billion | DKK 55.5 billion | |
| 2023 | DKK 232 billion | DKK 83.7 billion | |
| 2024 | DKK 290 billion | DKK 101 billion | |
| 2025 | DKK 309 billion | DKK 102 billion |
As reported in its annual filings, in DKK. Losses in red.
Stratrix Decision Cases
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Denmark, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.